CR10545A - Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso - Google Patents

Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso

Info

Publication number
CR10545A
CR10545A CR10545A CR10545A CR10545A CR 10545 A CR10545 A CR 10545A CR 10545 A CR10545 A CR 10545A CR 10545 A CR10545 A CR 10545A CR 10545 A CR10545 A CR 10545A
Authority
CR
Costa Rica
Prior art keywords
oxo
prolinamida
fenilmetil
replaced
methods
Prior art date
Application number
CR10545A
Other languages
English (en)
Inventor
Laura J Chambers
Robert Gleave
Stefan Senger
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613473A external-priority patent/GB0613473D0/en
Priority claimed from GB0622825A external-priority patent/GB0622825D0/en
Priority claimed from GB0705263A external-priority patent/GB0705263D0/en
Priority claimed from GB0711439A external-priority patent/GB0711439D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10545A publication Critical patent/CR10545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a nuevos derivados de oxo-prolinamida de formula (I) que modulan la funcion del receptor P2X7y son capaces de antagonizar los efectos de ATP en el receptor P2X7 y al uso de dichos compuestos o sus composiciones farmaceuticas en el tratamiento de trastornos mediados por el receptor P2X7, por ejemplo dolor, inflamacion y neurodegeneracion.
CR10545A 2006-07-06 2008-12-19 Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso CR10545A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0613473A GB0613473D0 (en) 2006-07-06 2006-07-06 Novel compounds
GB0622825A GB0622825D0 (en) 2006-11-15 2006-11-15 Novel compounds
GB0705263A GB0705263D0 (en) 2007-03-19 2007-03-19 Novel compounds
GB0711439A GB0711439D0 (en) 2007-06-13 2007-06-13 Novel receptor antagonists and their methods of use

Publications (1)

Publication Number Publication Date
CR10545A true CR10545A (es) 2009-01-27

Family

ID=38508907

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10545A CR10545A (es) 2006-07-06 2008-12-19 Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
CR20140515A CR20140515A (es) 2006-07-06 2014-11-10 Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140515A CR20140515A (es) 2006-07-06 2014-11-10 Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso

Country Status (25)

Country Link
US (2) US7718693B2 (es)
EP (1) EP2049478B1 (es)
JP (1) JP5283620B2 (es)
KR (2) KR20140016431A (es)
AR (1) AR061815A1 (es)
AU (1) AU2007271182B2 (es)
BR (1) BRPI0714062A2 (es)
CA (1) CA2655675A1 (es)
CR (2) CR10545A (es)
CY (1) CY1113415T1 (es)
DK (1) DK2049478T3 (es)
EA (1) EA016076B1 (es)
ES (1) ES2385505T3 (es)
HR (1) HRP20120505T1 (es)
IL (1) IL196181A0 (es)
MA (1) MA30607B1 (es)
MX (1) MX2009000117A (es)
NO (1) NO20090267L (es)
PE (1) PE20080997A1 (es)
PL (1) PL2049478T3 (es)
PT (1) PT2049478E (es)
SI (1) SI2049478T1 (es)
TW (1) TW200819127A (es)
UA (1) UA100227C2 (es)
WO (1) WO2008003697A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
DE102006047619B4 (de) * 2006-10-09 2008-11-13 Clariant International Limited Verfahren zur Herstellung basischer Fettsäureamide
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
AU2007309081B2 (en) * 2006-10-22 2012-08-30 Idev Technologies, Inc. Methods for securing strand ends and the resulting devices
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
US20100168171A1 (en) * 2007-03-28 2010-07-01 Paul John Beswick Piperidinone Carboxamide Derivatives as P2X7 Modulators
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
CN101679291A (zh) * 2007-04-03 2010-03-24 葛兰素集团有限公司 作为p2x7调节剂的咪唑烷甲酰胺衍生物
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
KR20100099178A (ko) * 2007-12-18 2010-09-10 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 5-옥소-3-피롤리딘카르복스아미드 유도체
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
MX2010007546A (es) 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
WO2009089459A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
US8232290B2 (en) 2008-03-25 2012-07-31 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
DE102008017218B4 (de) * 2008-04-04 2011-09-22 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren
DE102008017215B4 (de) * 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
DE102008017217A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren
DE102008017214B4 (de) * 2008-04-04 2012-02-16 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden
DE102008017213B4 (de) * 2008-04-04 2012-08-09 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren
DE102008017216B4 (de) * 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
DE102008017219A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser
JP5583694B2 (ja) * 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
EP2243772B1 (en) 2009-04-14 2012-01-18 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
AU2010328203B2 (en) 2009-12-08 2014-05-15 The United States Government As Represented By The Department Of Veterans Affairs Improved methods and compositions for vein harvest and autografting
CA2792258A1 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP3009427B1 (en) * 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101995088B1 (ko) 2011-07-22 2019-07-02 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
MX336247B (es) 2012-01-20 2016-01-13 Actelion Pharmaceuticals Ltd Derivados de amida heterociclicos como antagonistas del receptor p2x7.
US9075975B2 (en) * 2012-02-21 2015-07-07 Andrew Bud Online pseudonym verification and identity validation
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
EP2956135B1 (en) 2013-01-22 2016-11-16 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
KR102220847B1 (ko) 2013-01-22 2021-02-26 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
FR3026102A1 (fr) * 2014-09-19 2016-03-25 Univ Nice Sophia Antipolis Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DE102016111711A1 (de) * 2016-06-27 2017-12-28 Abb Schweiz Ag Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme
PT3609868T (pt) * 2017-03-13 2023-12-18 Raqualia Pharma Inc Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
WO2019006074A1 (en) * 2017-06-28 2019-01-03 Indiana University Research And Technology Corporation PHARMACEUTICAL AGENT THAT RELATES TO THE P2X7 RECEIVER
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibitor
IL277602B2 (en) 2018-03-29 2024-06-01 Centre Nat Rech Scient P2RX7 modulators in therapy
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
ES3032941T3 (en) 2020-03-31 2025-07-29 Remicine Ip B V Treatment of hyperinflammatory syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651639A (en) * 1951-08-22 1953-09-08 American Cyanamid Co 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same
FR2273533A1 (fr) * 1974-06-04 1976-01-02 Ferlux Sa Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5
JPH0699307B2 (ja) 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
US4772601A (en) 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use
JP2000500464A (ja) 1995-11-13 2000-01-18 スミスクライン・ビーチャム・コーポレイション 血液調節化合物
US6054579A (en) * 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CA2355296A1 (en) 1998-12-11 2000-06-15 American Biogenetic Sciences, Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CN1215028C (zh) 2002-05-24 2005-08-17 中国科学院上海有机化学研究所 外消旋的联二酚的光学拆分方法
US7288538B2 (en) * 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
AU2004273610B2 (en) * 2003-09-22 2010-07-01 Onepharm Research & Development Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2007115403A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20080076924A1 (en) * 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
PT2046740E (pt) * 2006-07-22 2012-08-28 Oxagen Ltd Compostos com atividade antagonista do crth2
EP2096923B1 (en) * 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
CA2680275C (en) * 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
US20100168171A1 (en) * 2007-03-28 2010-07-01 Paul John Beswick Piperidinone Carboxamide Derivatives as P2X7 Modulators
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
CN101679291A (zh) * 2007-04-03 2010-03-24 葛兰素集团有限公司 作为p2x7调节剂的咪唑烷甲酰胺衍生物
CN101772498A (zh) * 2007-04-10 2010-07-07 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物

Also Published As

Publication number Publication date
CR20140515A (es) 2014-12-01
AU2007271182B2 (en) 2012-03-15
MX2009000117A (es) 2009-01-23
PE20080997A1 (es) 2008-10-02
EA200970085A1 (ru) 2009-06-30
CY1113415T1 (el) 2016-06-22
PL2049478T3 (pl) 2012-09-28
KR101398264B1 (ko) 2014-05-26
SI2049478T1 (sl) 2012-08-31
US8048907B2 (en) 2011-11-01
US20080009541A1 (en) 2008-01-10
EP2049478A1 (en) 2009-04-22
PT2049478E (pt) 2012-07-16
HRP20120505T1 (hr) 2012-07-31
US20100144829A1 (en) 2010-06-10
JP2009542595A (ja) 2009-12-03
CA2655675A1 (en) 2008-01-10
MA30607B1 (fr) 2009-07-01
UA100227C2 (uk) 2012-12-10
US7718693B2 (en) 2010-05-18
AR061815A1 (es) 2008-09-24
AU2007271182A1 (en) 2008-01-10
ES2385505T3 (es) 2012-07-25
TW200819127A (en) 2008-05-01
WO2008003697A1 (en) 2008-01-10
NO20090267L (no) 2009-03-09
KR20090028808A (ko) 2009-03-19
EP2049478B1 (en) 2012-05-30
KR20140016431A (ko) 2014-02-07
JP5283620B2 (ja) 2013-09-04
HK1127604A1 (en) 2009-10-02
BRPI0714062A2 (pt) 2012-12-18
IL196181A0 (en) 2009-09-22
DK2049478T3 (da) 2012-07-09
EA016076B1 (ru) 2012-01-30

Similar Documents

Publication Publication Date Title
CR10545A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
UY32996A (es) Antagonistas del receptor crth2 basados en indol
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
CR20190567A (es) Derivados de indol n-sustituidos
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3